ASDR of Tuberculosis for the 21 Global Burden of Disease regions by SDI, 1990-2021. by Xue Li (285380)

Subjects:

The incidence, death and DALYs in individuals aged 0 to 19 years in 204 countries and territories in 2021. by Xue Li (285380)

Subjects:

Composition ratio of each type of tuberculosis age-standardized incidence rate in 21 regions in 1990 and 2021. by Xue Li (285380)

Subjects:

Each types of tuberculosis ASMR in 1990 and 2021. by Xue Li (285380)

Subjects:

DALYs, ASDR, and Relative change of Tuberculosis in children and Adolescence in global and 21 regions, with EAPC from 1990 and 2021. by Xue Li (285380)

Subjects:

Age standardized incidence rates of Tuberculosis for the 21 Global Burden of Disease regions by SDI, 1990-2021. by Xue Li (285380)

Subjects:

Death number, ASMR under the age of 20 in 204 countries and territories in 2021. by Xue Li (285380)

Subjects:

ASMR of Tuberculosis for the 21 Global Burden of Disease regions by SDI, 1990-2021. by Xue Li (285380)

Subjects:

Each types of tuberculosis ASDR in 1990 and 2021. by Xue Li (285380)

Subjects:

Each types of tuberculosis ASIR in 1990 and 2021. by Xue Li (285380)

Subjects:

Death, ASMR, and Relative change of Tuberculosis in children and Adolescence in global and 21 regions, with EAPC from 1990 and 2021. by Xue Li (285380)

Subjects:

Incidence, death and DALYs of TB, by age and sex in 2021. by Xue Li (285380)

Subjects:

Composition ratio of each types of tuberculosis ASDR in 1990 and 2021. by Xue Li (285380)

Subjects:

Incidence number, ASIR under the age of 20 in 204 countries and territories in 2021. by Xue Li (285380)

Subjects:

Composition ratio of each types of tuberculosis ASMR in 1990 and 2021. by Xue Li (285380)

Subjects:

DALYs number, ASDR under the age of 20 in 204 countries and territories in 2021. by Xue Li (285380)

Subjects:

Trends in voluntary disclosure report names for Japanese Listed Companies 2008-2023. by Yuichiro Nakai (689312)

“…<p>This figure highlights the significant increase in the number of Integrated Reports and Company Name Reports, as well as the notable decrease in the number of Annual Reports issued by Japanese listed companies from 2008 to 2023.…”

Genomic downregulation of TGF β1 production in monocytes obtained after RZV administration. Panel A. The heatmap shows 16 genes on the y axis whose accessibility significantly chan... by Michael J. Johnson (5818168)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”